Does Rallies show Form 4 insider transactions for TBPH?

Yes. Rallies tracks TBPH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is TBPH research on Rallies investment advice?

No. Rallies provides research, data, and educational context for TBPH. It does not provide personalized investment advice.

TBPH (Theravance Biopharma, Inc.) Stock Analysis - Insider Trades

Theravance Biopharma, Inc. (TBPH) is a publicly traded Healthcare sector company. As of May 21, 2026, TBPH trades at $16.55 with a market cap of $838.25M and a P/E ratio of 7.31. TBPH moved +1.72% today. Year to date, TBPH is -10.15%; over the trailing twelve months it is +75.13%. Its 52-week range spans $7.88 to $21.03. Analyst consensus is buy with an average price target of $16.61. Rallies surfaces TBPH's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading TBPH stock inside the company?

Recent TBPH insider activity includes Farnum Rhonda sold 7.77K, Farnum Rhonda sold 15.53K, Farnum Rhonda sold 7.77K, Farnum Rhonda sold 7.77K, and Farnum Rhonda sold 7.77K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

TBPH Key Metrics

Key financial metrics for TBPH
Metric	Value
Price	$16.55
Market Cap	$838.25M
P/E Ratio	7.31
EPS	$2.26
Dividend Yield	0.00%
52-Week High	$21.03
52-Week Low	$7.88
Volume	0
Avg Volume	0
Revenue (TTM)	$109.78M
Net Income	$114.54M
Gross Margin	0.00%

Recent TBPH Insider Trades

Farnum Rhonda sold 7.77K (~$108.09K) on Mar 16, 2026.
Farnum Rhonda sold 15.53K (~$217.48K) on Mar 16, 2026.
Farnum Rhonda sold 7.77K (~$108.07K) on Mar 16, 2026.
Farnum Rhonda sold 7.77K (~$145.63K) on Dec 3, 2025.
Farnum Rhonda sold 7.77K (~$145.62K) on Dec 3, 2025.

Latest TBPH News

Q1 Collaboration Revenue Rises 15% to $17.7M as Costs Drop 20% — May 7, 2026
Theravance Biopharma Posts $61m Q4 Profit, EPS Miss Triggers 60% Cost-Cut Plan — Mar 19, 2026
Theravance Biopharma Shares Fall 33.7%, RSI at 21.5 Signals Oversold — Mar 9, 2026
Theravance Biopharma Shares Drop 26% as Ampreloxetine Trial Fails, Cuts Jobs 50% — Mar 4, 2026
Theravance Halves Workforce, Shuts R&D to Save $70M After Trial Failure — Mar 4, 2026

TBPH Analyst Consensus

6 analysts cover TBPH: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $16.61.

Common questions about TBPH

Who is trading TBPH stock inside the company?: Recent TBPH insider activity includes Farnum Rhonda sold 7.77K, Farnum Rhonda sold 15.53K, Farnum Rhonda sold 7.77K, Farnum Rhonda sold 7.77K, and Farnum Rhonda sold 7.77K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for TBPH?: Yes. Rallies tracks TBPH insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is TBPH research on Rallies investment advice?: No. Rallies provides research, data, and educational context for TBPH. It does not provide personalized investment advice.